- Amended Quarterly Report (10-Q/A)
August 27 2012 - 6:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
|
Washington, D.C. 20549
|
|
|
FORM 10
-
Q/A
|
(Mark One)
|
|
|
|
[X]
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
For the quarterly period ended:
June 30, 2012
|
|
|
[ ]
|
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from
_________________to________________
Commission File Number: 001-34566
CHINA BIOLOGIC PRODUCTS,
INC.
(Exact Name of Registrant as Specified in
Its Charter)
Delaware
|
75-2308816
|
(State or other jurisdiction of
|
(I.R.S. Employer Identification No.)
|
incorporation or organization)
|
|
18th Floor, Jialong International Building
19 Chaoyang
Park Road
Chaoyang District, Beijing 100125
Peoples Republic of
China
(Address of principal executive offices, Zip Code)
(+86) 10-6598-3111
(Registrants telephone number,
including area code)
_____________________________________________________
(Former
name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files).
Yes [X] No [ ]
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer,
accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act.
Large accelerated filer [ ]
|
|
Accelerated filer [X]
|
|
|
|
Non-accelerated filer [ ]
(Do not check if a
smaller reporting company)
|
|
Smaller reporting company [ ]
|
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
Yes [ ] No [X]
The number of shares outstanding of each of the issuers
classes of common stock, as of August 6, 2012 is as follows:
Class of
Securities
|
|
Shares Outstanding
|
Common Stock, $0.0001 par value
|
|
26,538,625
|
EXPLANATORY NOTE
The sole purpose of this Amendment to the Registrants
Quarterly Report on Form 10-Q for the period ended June 30, 2012 (the 10-Q),
is to furnish the Interactive Data File exhibits pursuant to Rule 405 of
Regulation S-T. No other changes have been made to the 10-Q, and this Amendment
has not been updated to reflect events occurring subsequent to the filing of the
10-Q.
PART II
OTHER INFORMATION
ITEM 6. EXHIBITS.
The following exhibits are filed as part of this report or
incorporated by reference:
Exhibit
No.
|
Description
|
|
|
31.1
*
|
Certifications of Principal
Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
|
31.2
*
|
Certifications of Principal Financial Officer
filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
32.1
*
|
Certifications of Principal
Executive Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
32.2
*
|
Certifications of Principal Financial Officer
furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.
|
101**
|
Interactive data files pursuant
to Rule 405 of Regulation S-T
|
* These exhibits were previously included in the Quarterly Report on Form
10-Q of China Biologic Products, Inc. for the quarterly period ended June 30,
2012, filed with the Securities and Exchange Commission on August 9, 2012.
** Filed with this Form 10-Q/A for China Biologic Products, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date: August 27, 2012
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
By:
|
/s/
David (Xiaoying) Gao
|
|
|
David (Xiaoying) Gao, Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
|
By:
|
/s/
Ming Yang
|
|
|
Ming Yang, Chief Financial Officer
|
|
|
(Principal Financial Officer and
Principal
|
|
|
Accounting Officer)
|
|
|
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024